TGTX
TG Therapeutics, Inc.
TG Therapeutics, Inc. insider trading
TG Therapeutics, Inc. files with the SEC as a Pharmaceutical Preparations company headquartered in New York, NY. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.
From SEC filings
Recent TGTX insider transactions
One insider traded TGTX on the open market on Sep 10, 2026 — 1 sale worth $274.8K.
- Bought
- —
- Sold
- $274.8K
- Net
- −$274.8K
- Insiders
- 1
none on a 10b5-1 plan
Charney Laurence N
Director
−$274.8K
Sep 10, 2026
5,000 sh · $54.96
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Sep 10, 2026 | Charney Laurence NDirector | 5,000 | $54.96 | −$274.8K |
SEC Form 4 data, Q3 2024 to Q2 2026
TGTX insider trading by quarter
Between Jul 01, 2024 and Jun 30, 2026, 4 insiders traded TGTX on the open market: 0 purchases and 8 sales worth $3.2M. In the last four quarters alone: 0 purchases and 2 sales ($835.1K), by 2 insiders.
| Quarter | Bought | Sold | Insiders |
|---|---|---|---|
| Q2 2026 | — | — | |
| Q1 2026 | — | — | |
| Q4 2025 | — | −$162.9K1 sale | |
| Q3 2025 | — | −$672.3K1 sale | |
| Q2 2025 | — | −$369.4K1 sale | |
| Q1 2025 | — | −$629.3K2 sales | |
| Q4 2024 | — | −$1.4M3 sales | |
| Q3 2024 | — | — |
- Largest sale
- −$755K of TGTX by Charney Laurence N (Director) on Nov 11, 2024.
Open-market transactions through Jun 30, 2026most recent first
Echelard Yann
Director
−$162.9K
Nov 24, 2025
5,000 sh · $32.57
Lonial Sagar
Director
−$672.3K
Sep 11, 2025
20,852 sh · $32.24
Echelard Yann
Director
−$369.4K
Jun 13, 2025
10,000 sh · $36.94
Power Sean A
CFO
−$285.9K
Jan 06, 2025
10,021 sh · $28.53
Power Sean A
CFO
−$343.4K
Jan 03, 2025
11,337 sh · $30.29
Charney Laurence N
Director
−$755K
Nov 11, 2024
25,000 sh · $30.20
Lonial Sagar
Director
−$152.2K
Nov 11, 2024
5,000 sh · $30.44
Echelard Yann
Director
−$489.6K
Nov 05, 2024
20,000 sh · $24.48
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Nov 24, 2025 | Echelard YannDirector | 5,000 | $32.57 | −$162.9K |
| Sep 11, 2025 | Lonial SagarDirector | 20,852 | $32.24 | −$672.3K |
| Jun 13, 2025 | Echelard YannDirector | 10,000 | $36.94 | −$369.4K |
| Jan 06, 2025 | Power Sean ACFO | 10,021 | $28.53 | −$285.9K |
| Jan 03, 2025 | Power Sean ACFO | 11,337 | $30.29 | −$343.4K |
| Nov 11, 2024 | Charney Laurence NDirector | 25,000 | $30.20 | −$755K |
| Nov 11, 2024 | Lonial SagarDirector | 5,000 | $30.44 | −$152.2K |
| Nov 05, 2024 | Echelard YannDirector | 20,000 | $24.48 | −$489.6K |
From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.
TG Therapeutics, Inc. company record
- SEC industry classification
- Pharmaceutical Preparations
- Headquarters
- New York, NY
- Incorporated in
- DE
- Listed on
- Nasdaq
- SEC Central Index Key
- 0001001316
- Previously filed as
- MANHATTAN PHARMACEUTICALS INC
Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.
After insiders bought TGTX
What the stock actually did in the 90 days following each open-market purchase
Don't check TGTX — let it ping you
Get told the moment an insider moves on TGTX
Pro watches TG Therapeutics, Inc. for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add TGTX to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.
The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.
How to read TGTX insider activity
- Open-market purchase (code P)
- An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
- Grants and option exercises (codes A, M)
- Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
- Cluster buy
- Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.
Other Health Care tickers
Questions
- Are TGTX insiders buying or selling?
- Between Sep 10, 2026 and Sep 10, 2026, 1 TG Therapeutics, Inc. insider made no open-market purchases and 1 sale worth $274.8K, a net sale of $274.8K.
- How much TGTX stock have insiders bought and sold in the last two years?
- Between Jul 01, 2024 and Jun 30, 2026, 4 TG Therapeutics, Inc. insiders made no open-market purchases and 8 sales worth $3.2M. In the four quarters to Jun 30, 2026: no purchases and 2 sales ($835.1K). The largest sale was Charney Laurence N selling $755K on Nov 11, 2024.
- What was the largest recent TGTX insider trade?
- Charney Laurence N (Director) sold $274.8K of TGTX stock on Sep 10, 2026 at about $54.96 a share.
- When did an insider last buy TGTX shares?
- No open-market purchase by a TG Therapeutics, Inc. insider appears in the filings from Sep 10, 2026 to Sep 10, 2026 — every recorded open-market transaction in that period was a sale.
- Where does TGTX insider trading data come from?
- From the Form 4 filings TG Therapeutics, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.
Get the free Insider Brief
Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.